How Has The CAR-T Therapy Market Size Evolved Historically?
The car-t therapy market has seen considerable growth due to a variety of factors.
• There has been a fast-paced expansion in the CAR-T therapy market in the recent few years, escalating from $2.53 billion in 2024 to an expected $3.01 billion in 2025. This indicates a compound annual growth rate (CAGR) of 18.9%.
The notable expansion during the historical period can be credited to the enhancement in healthcare spending, accelerated investment in pharmaceutical research and development, along with progress in drug discovery.
What is the Forecasted Growth of the CAR-T Therapy Market Size?
The car-t therapy market is expected to maintain its strong growth trajectory in upcoming years.
• There's an anticipation for accelerated expansion in the CAR-T therapy market in the upcoming years, with an expected growth to $5.42 billion by 2029, recording a compound annual growth rate (CAGR) of 15.9%.
Factors contributing to this progression in the forecast period include the increasing rate of blood cancer cases, rising healthcare spending, a robust pipeline of medicines, and a heightened focus on CAR-T therapy. Some key trends projected in this period involve investment in research and development for redesigned CAR-T therapy to minimize neurologic side effects, development of off-the-shelf allogeneic CAR-T therapy for progressive cancer treatment, production of advanced CAR T cells to enhance treatment of high-grade glioma, utilization of artificial intelligence and machine learning to refine future CAR-T therapy, implementing strategic partnerships to foster innovation, collaboration or acquisition of rival firms to broaden the CAR-T therapy suite, and investment in CAR-T therapy for improved effectiveness.
What Are The Key Drivers Fueling Growth In The CAR-T Therapy Market?
The growth of the CAR-T therapy market is primarily fueled by the amplified financial backing provided by different entities in order to help foster the creation and utilization of CAR-T therapy. Comprehensive financial assistance is given to CAR-T therapy research and development corporations, and to patients suffering from acute lymphoblastic leukemia (ALL) by both governmental and non-governmental bodies. As an example, the U.S. health care spending, as reported by the Centers for Medicare and Medicaid Services, a US federal agency, expanded by 4.1% to reach a value of $4.5 trillion in 2022, an increase from growth of 3.2% in 2021. Moreover, there was an increase of 2.2% in spending on hospital care services in 2022, which amounted to $1.4 trillion. This financial sponsorship from various establishments has a positive influence on the expansion of the CAR-T therapy market.
What Is The Segmentation Of The Global CAR-T Therapy Market?
The CAR-T therapy market covered in this report is segmented –
1) By Type: Monotherapy, Combination Therapy
2) By Target Antigen: CD19, CD22, BCMA, Other Target Antigens
3) By Application: Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma, Other Applications
Subsegments:
1) By Monotherapy: CD19-targeted CAR-T Therapy, BCMA-Targeted CAR-T Therapy
2) By Combination Therapy: CAR-T Therapy With Immune Checkpoint Inhibitors, CAR-T Therapy With Other Targeted Therapies, CAR-T Therapy With Chemotherapy Or Radiotherapy
Pre-Book The CAR-T Therapy Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Shaping The CAR-T Therapy Market Landscape?
Leading companies in the CAR-T therapy market are emphasizing on creating technologically superior solutions such as diagnostic tools, with the aim of augmenting treatment customization and improving patient results. Diagnostic tools, including software, devices or instruments that enable identification and illness analysis, condition, or other health complications. Such tools could range from screening, imaging machinery, or lab evaluations that offer insight into a patient's health condition, assisting in precise diagnosis and effectual treatment plan. For example, Eurofins Viracor, an American clinical diagnostic lab, introduced the ExPeCT Expansion and Persistence of CAR T Assay in February 2023. This tool is beneficial for tracking patients on CAR T cell therapy because it allows continuous monitoring of CAR T cell growth and persistence, offering instant data to gauge treatment effectiveness and patient supervision. Besides, the assay can help detect patients susceptible to treatment failure due to subpar CAR T cell dynamics, enabling timely intervention that could enhance clinical results in hematological cancers.
Who Are the Key Players in the CAR-T Therapy Market?
Major companies operating in the CAR-T therapy market include:
• Gilead Sciences
• Novartis AG
• Biocon
• Gracell Biotechnology Ltd
• Aeon Therapeutics
• CARsgen Therapeutics
• Daiichi Sankyo
• Otsuka Pharmaceutical
• Ono Pharmaceutical
• Takeda Pharmaceutical Company
• Astellas Pharma
• Innovative Cellular Therapeutics
• Cellular Biomedicine Group
• PersonGen Biomedicine
• Hebei Senlang Biotech
• Adaptimmune(UK)
• Autolus Therapeutics
• BioNTech
• Cellectis
• Celyad
• Crescendo Biologics
• GammaDelta Therapeutics
• Immatics
• Biocad
• Celgene Corporation
• Johnson & Johnson
• F. Hoffmann-La Roche Ltd
• Eli Lilly and Company
• Amgen
• AstraZeneca
• Bayer AG
• Merck
• Pfizer
• Juno Therapeutics
• Allogene Therapeutics
• Regen BioPharma
• OncoSec Medical Incorporated
• Precision BioSciences
• Bellicum
• Sandoz AG
• GlaxoSmithKline plc
What are the Regional Insights into the CAR-T Therapy Market?
North America was the largest region in the CAR-T therapy market in 2024. Western Europe was the second-largest region in the global CAR-T therapy market share. The regions covered in the CAR-T Therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
